CTNM PE Ratio & Valuation,Is CTNM Overvalued

CTNM Relative Valuation

CTNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTNM is overvalued; if below, it's undervalued.

Historical Valuation

Contineum Therapeutics Inc (CTNM) is now in the Fair zone, suggesting that its current forward PS ratio of 31.21 is considered Fairly compared with the five-year average of -6.65. The fair price of Contineum Therapeutics Inc (CTNM) is between 5.58 to 20.20 according to relative valuation methord.

Relative Value

Fair Zone

5.58-20.20

Current Price：9.56

Fair

-5.76

-1.73

EV/EBITDA

Contineum Therapeutics Inc. (CTNM) has a current EV/EBITDA of -1.73. The 5-year average EV/EBITDA is -3.71. The thresholds are as follows: Strongly Undervalued below -12.73, Undervalued between -12.73 and -8.22, Fairly Valued between 0.80 and -8.22, Overvalued between 0.80 and 5.30, and Strongly Overvalued above 5.30. The current Forward EV/EBITDA of -1.73 falls within the Historic Trend Line -Fairly Valued range.

-2.04

EV/EBIT

Contineum Therapeutics Inc. (CTNM) has a current EV/EBIT of -2.04. The 5-year average EV/EBIT is -3.96. The thresholds are as follows: Strongly Undervalued below -13.38, Undervalued between -13.38 and -8.67, Fairly Valued between 0.75 and -8.67, Overvalued between 0.75 and 5.46, and Strongly Overvalued above 5.46. The current Forward EV/EBIT of -2.04 falls within the Historic Trend Line -Fairly Valued range.

31.21

Contineum Therapeutics Inc. (CTNM) has a current PS of 31.21. The 5-year average PS is 50.80. The thresholds are as follows: Strongly Undervalued below -8.87, Undervalued between -8.87 and 20.96, Fairly Valued between 80.63 and 20.96, Overvalued between 80.63 and 110.46, and Strongly Overvalued above 110.46. The current Forward PS of 31.21 falls within the Historic Trend Line -Fairly Valued range.

-6.13

P/OCF

Contineum Therapeutics Inc. (CTNM) has a current P/OCF of -6.13. The 5-year average P/OCF is -7.77. The thresholds are as follows: Strongly Undervalued below -17.01, Undervalued between -17.01 and -12.39, Fairly Valued between -3.14 and -12.39, Overvalued between -3.14 and 1.48, and Strongly Overvalued above 1.48. The current Forward P/OCF of -6.13 falls within the Historic Trend Line -Fairly Valued range.

-6.13

P/FCF

Contineum Therapeutics Inc. (CTNM) has a current P/FCF of -6.13. The 5-year average P/FCF is -7.26. The thresholds are as follows: Strongly Undervalued below -15.46, Undervalued between -15.46 and -11.36, Fairly Valued between -3.17 and -11.36, Overvalued between -3.17 and 0.93, and Strongly Overvalued above 0.93. The current Forward P/FCF of -6.13 falls within the Historic Trend Line -Fairly Valued range.

Contineum Therapeutics Inc (CTNM) has a current Price-to-Book (P/B) ratio of 1.84. Compared to its 3-year average P/B ratio of 1.24 , the current P/B ratio is approximately 48.61% higher. Relative to its 5-year average P/B ratio of 1.24, the current P/B ratio is about 48.61% higher. Contineum Therapeutics Inc (CTNM) has a Forward Free Cash Flow (FCF) yield of approximately -15.89%. Compared to its 3-year average FCF yield of -14.45%, the current FCF yield is approximately 10.00% lower. Relative to its 5-year average FCF yield of -14.45% , the current FCF yield is about 10.00% lower.

1.84

P/B

Median3y

1.24

Median5y

1.24

-15.89

FCF Yield

Median3y

-14.45

Median5y

-14.45

Competitors Valuation Multiple

The average P/S ratio for CTNM's competitors is 6.24, providing a benchmark for relative valuation. Contineum Therapeutics Inc Corp (CTNM) exhibits a P/S ratio of 31.21, which is 400% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CTNM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CTNM in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Contineum Therapeutics Inc (CTNM) currently overvalued or undervalued?

What is Contineum Therapeutics Inc (CTNM) fair value?

CTNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Contineum Therapeutics Inc (CTNM) is between 5.58 to 20.20 according to relative valuation methord.

How does CTNM's valuation metrics compare to the industry average?

The average P/S ratio for CTNM's competitors is 6.24, providing a benchmark for relative valuation. Contineum Therapeutics Inc Corp (CTNM) exhibits a P/S ratio of 31.21, which is 400.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Contineum Therapeutics Inc (CTNM) as of Jan 08 2026?

As of Jan 08 2026, Contineum Therapeutics Inc (CTNM) has a P/B ratio of 1.84. This indicates that the market values CTNM at 1.84 times its book value.

What is the current FCF Yield for Contineum Therapeutics Inc (CTNM) as of Jan 08 2026?

As of Jan 08 2026, Contineum Therapeutics Inc (CTNM) has a FCF Yield of -15.89%. This means that for every dollar of Contineum Therapeutics Inc’s market capitalization, the company generates -15.89 cents in free cash flow.

What is the current Forward P/E ratio for Contineum Therapeutics Inc (CTNM) as of Jan 08 2026?

As of Jan 08 2026, Contineum Therapeutics Inc (CTNM) has a Forward P/E ratio of -5.76. This means the market is willing to pay $-5.76 for every dollar of Contineum Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Contineum Therapeutics Inc (CTNM) as of Jan 08 2026?

As of Jan 08 2026, Contineum Therapeutics Inc (CTNM) has a Forward P/S ratio of 31.21. This means the market is valuing CTNM at $31.21 for every dollar of expected revenue over the next 12 months.

CTNM Valuation